Bio-Rad launches four new digital PCR platforms following acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
July 7, 2025 9:00 AM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include Bio-Rads QX Continuum ddPCR system along with the QX700 series of ddPCR platforms acquired as part of the companys recently completed acquisition of digital PCR developer Stilla Technologies.
Together with Bio-Rads existing line of QX200 and QX600 ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science... More
